Abstracts
16 June 2009
Vol. 2 No. 15 (2006)
https://doi.org/10.4081/hmr.v2i15.607

Secondary Myeloid Malignancy after Treatment of Acute Lymphoblastic Leukemia (ALL)

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
200
Views
214
Downloads

Authors

Mary V. Relling
support@pagepress.org
Treatment of childhood acute lymphoblastic leukemia (ALL) has made tremendous strides over the past 20 years, but has been complicated by the induction of secondary tumors after some regimens. The cumulative incidence of therapy-related myeloid leukemia and myelodysplastic syndrome (referred to collectively as t-ML) varies widely among treatment protocols, from 1% to 12%.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Secondary Myeloid Malignancy after Treatment of Acute Lymphoblastic Leukemia (ALL). (2009). Hematology Meeting Reports, 2(15). https://doi.org/10.4081/hmr.v2i15.607